Abstract:Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead compounds during preclinical and clinical studies as they link drug-target inhibition in cells with biological activity. They are of particular importance for novel, first-in-class mechanisms, where the ability of a targeted therapeutic to impact disease outcome is often unknown. By definition, proximal PD biomarkers aim to measure the interaction of a drug with its biological target. For kinase drug discovery, protein substrate phosphorylation sites represent candidate PD biomarkers. However, substrate phosphorylation is often controlled by input from multiple converging pathways complicating assessment of how potently a small molecule drug hits its target based on substrate phoshorylation measurements alone. Here, we report the use of quantitative, differential mass-spectrometry to identify and monitor novel drug-regulated phosphorylation sites on target kinases. Autophosphorylation sites constitute clinically validated biomarkers for select protein tyrosine kinase inhibitors. The present study extends this principle to phosphorylation sites in serine/threonine kinases looking beyond the T-loop autophosphorylation site. Specifically, for the 3'-phosphoinositide-dependent protein kinase 1 (PDK1), two phospho-residues p-PDK1(Ser410) and p-PDK1(Thr513) are modulated by small-molecule PDK1 inhibitors, and their degree of dephosphorylation correlates with inhibitor potency. We note that classical, ATP-competitive PDK1 inhibitors do not modulate PDK1 T-loop phosphorylation (p-PDK1(Ser241)), highlighting the value of an unbiased approach to identify drug target-regulated phosphorylation sites as these are complementary to pathway PD biomarkers. Finally, we extend our analysis to another protein Ser/Thr kinase, highlighting a broader utility of our approach for identification of kinase drug-target engagement biomarkers.

A strategy to disentangle direct and indirect effects on (de)phosphorylation by chemical modulators of the phosphatase PP1 in complex cellular contexts

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

Palladium-Triggered Deprotection Chemistry for Protein Activation in Living Cells

A chemical-genetic system to rapidly inhibit the PP2A-B56 phosphatase

Short peptide pharmacophores developed from protein phosphatase-1 disrupting peptides (PDPs)

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform

A Quantitative Chemical Proteomic Strategy for Profiling Phosphoprotein Phosphatases from Yeast to Humans

Coupling substrate-trapping with proximity-labeling to identify protein tyrosine phosphatase PTP1B signaling networks

Inducible degradation-coupled phosphoproteomics identifies PP2ARts1 as a novel eisosome regulator

Reversible control of kinase signaling through chemical-induced dephosphorylation

Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.

Identification of Direct Target Engagement Biomarkers for Kinase-Targeted Therapeutics.

Previously Published Phosphatase Probes Have Limited Utility Due To Their Unspecific Reactivity

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Targeting phosphatases: From molecule design to clinical trials

Heterobifunctional molecules tackle targeted protein dephosphorylation

Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation

Peptide microarrays for high-throughput studies of Ser/Thr phosphatases

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Dissecting the functional behavior of the differentially phosphorylated prolyl isomerase, Pin1